Compare General Mills, Inc. (GIS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Medpace Holdings Inc — how do they compare? General Mills, Inc. trades at $32.29 (market cap $17.43B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: General Mills, Inc. and Medpace Holdings Inc are close in size by market cap, and General Mills, Inc. pays a 7.49% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Medpace Holdings Inc for 14 Days on average.
| GIS | MEDP | |
|---|---|---|
Market Cap | $17.43B | $16.82B |
Volume | 16,554,362 | 223,093 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $630.19 |
52-Week Low | $31.67 | $393.42 |
Typical Hold Time | 106 Days | 14 Days |
Enterprise Value | $30.61B | $16.44B |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.59, up 2.58% today, amid a bearish technical outlook. The stock shows mixed fundamentals with a low P/E of 9.23 and a dividend yield supported by a $0.61 quarterly payout, but profitability metrics like a negative net income margin and ROE highlight challenges. Recent Q1 2027 earnings beat expectations, yet revenue trends are declining, and a CEO transition adds uncertainty. Analyst consensus is cautious with a $36.00 price target and a majority hold rating.
The outlook remains guarded due to margin pressures and competitive headwinds, though the dividend offers income appeal. Risks include potential earnings volatility and high debt levels. Upside depends on successful execution of cost-saving initiatives and volume recovery, but near-term performance may be constrained by macroeconomic factors.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
